Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations with Subclinical Vascular Brain Injury and Incident Stroke

Stroke

Volumn 46, Issue 9, 2015, Pages 2568-2575

  Andersson, Charlotte ^a,b   Preis, Sarah R ^c,d   Beiser, Alexa ^a,c,d   DeCarli, Charles ^e   Wollert, Kai C ^f   Wang, Thomas J ^a,g   Januzzi, James L ^h   Vasan, Ramachandran S ^a,d   Seshadri, Sudha ^a  

^a FRAMINGHAM HEART STUDY   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g VANDERBILT UNIVERSITY   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

follow up studies; growth differentiation factor 15; magnetic resonance imaging; neuroimaging; stroke

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; PEPTIDES AND PROTEINS; SOLUBLE ST2; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD VESSEL INJURY; BRAIN DAMAGE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN SIZE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SMOKING; SUBCLINICAL VASCULAR BRAIN INJURY; SYSTOLIC BLOOD PRESSURE; WHITE MATTER; AGED; BLOOD; BRAIN; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; PATHOLOGY; PATHOPHYSIOLOGY; TRANSIENT ISCHEMIC ATTACK;

AGED; BIOMARKERS; BRAIN; CEREBROVASCULAR TRAUMA; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; STROKE;

EID: 84940390238     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.009026     Document Type: Article

References (41)

1. Heil DP. Predicting activity energy expenditure using the Actical activity monitor. Res Q Exerc Sport. 2006;77:64-80. doi: 10.1080/02701367.2006.10599333.
2. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611-619. doi: 10.1016/S1474-4422(07)70170-9.
3. Kernagis DN, Laskowitz DT. Evolving role of biomarkers in acute cerebrovascular disease. Ann Neurol. 2012;71:289-303. doi: 10.1002/ana.22553.
4. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009;30:2346-2353. doi: 10.1093/eurheartj/ehp261.
5. Izumiya Y, Hanatani S, Kimura Y, Takashio S, Yamamoto E, Kusaka H, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol. 2014;30:338-344. doi: 10.1016/j.cjca.2013.12.010.
6. Schaub N, Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, et al. Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain. Clin Chem. 2012;58:441-449. doi: 10.1373/clinchem.2011.173310.
7. Schopfer DW, Ku IA, Regan M, Whooley MA. Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). Am Heart J. 2014;167:186-192.e1. doi: 10.1016/j.ahj.2013.09.013.
8. Kempf T, Björklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28:2858-2865. doi: 10.1093/eurheartj/ehm465.
9. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116:1540-1548. doi: 10.1161/CIRCULATIONAHA.107.697714.
10. Gröschel K, Schnaudigel S, Edelmann F, Niehaus CF, Weber-Krüger M, Haase B, et al. Growth-differentiation factor-15 and functional outcome after acute ischemic stroke. J Neurol. 2012;259:1574-1579. doi: 10.1007/s00415-011-6379-0.
11. Worthmann H, Kempf T, Widera C, Tryc AB, Goldbecker A, Ma YT, et al. Growth differentiation factor 15 plasma levels and outcome after ischemic stroke. Cerebrovasc Dis. 2011;32:72-78. doi: 10.1159/000328233.
12. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126:1596-1604. doi: 10.1161/CIRCULATIONAHA.112.129437.
13. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation. 2011;123:2101-2110. doi: 10.1161/CIRCULATIONAHA.110.979740.
14. Ho JE, Mahajan A, Chen MH, Larson MG, McCabe EL, Ghorbani A, et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem. 2012;58:1582-1591. doi: 10.1373/clinchem.2012.190322.
15. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012;58:257-266. doi: 10.1373/clinchem.2011.173369.
16. Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB, et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol. 2013;167:2182-2188. doi: 10.1016/j. ijcard.2012.05.073.
17. Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol. 2014;172:e250-e252. doi: 10.1016/j.ijcard.2013.12.101.
18. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012;58:1673-1681. doi: 10.1373/clinchem.2012.192153.
19. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281-290.
20. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639. doi: 10.1056/NEJMoa055373.
21. Rienstra M, Yin X, Larson MG, Fontes JD, Magnani JW, McManus DD, et al. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J. 2014;167:109-115.e2. doi: 10.1016/j.ahj.2013.10.003.
22. Xanthakis V, Larson MG, Wollert KC, Aragam J, Cheng S, Ho J, et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc. 2013;2:e000399. doi: 10.1161/JAHA.113.000399.
23. DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging. 2005;26:491-510. doi: 10.1016/j.neurobiolaging.2004.05.004.
24. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol. 2006;63:246-250. doi: 10.1001/archneur.63.2.246.
25. Pikula A, Beiser AS, Chen TC, Preis SR, Vorgias D, DeCarli C, et al. Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study. Stroke. 2013;44:2768-2775. doi: 10.1161/STROKEAHA.113.001447.
26. Tsao CW, Seshadri S, Beiser AS, Westwood AJ, Decarli C, Au R, et al. Relations of arterial stiffness and endothelial function to brain aging in the community. Neurology. 2013;81:984-991. doi: 10.1212/WNL.0b013e3182a43e1c.
27. Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Beiser A, Au R, et al. Framingham stroke risk profile and lowered cognitive performance. Stroke. 2004;35:404-409. doi: 10.1161/01.STR.0000103141.82869.77.
28. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
29. Seshadri S, Wolf PA, Beiser A, Elias MF, Au R, Kase CS, et al. Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology. 2004;63:1591-1599.
30. Pikula A, Beiser AS, DeCarli C, Himali JJ, Debette S, Au R, et al. Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation. 2012;125:2100-2107. doi: 10.1161/CIRCULATIONAHA.110.989145.
31. Mazagova M, Buikema H, Landheer SW, Vavrinec P, Buiten Av, Henning RH, et al. Growth differentiation factor 15 impairs aortic contractile and relaxing function through altered caveolar signaling of the endothelium. Am J Physiol Heart Circ Physiol. 2013;304:H709-H718. doi: 10.1152/ajpheart.00543.2012.
32. Schober A, Böttner M, Strelau J, Kinscherf R, Bonaterra GA, Barth M, et al. Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol. 2001;439:32-45. doi: 10.1002/cne.1333.
33. Schindowski K, von Bohlen und Halbach O, Strelau J, Ridder DA, Herrmann O, Schober A, et al. Regulation of GDF-15, a distant TGF-β superfamily member, in a mouse model of cerebral ischemia. Cell Tissue Res. 2011;343:399-409. doi: 10.1007/s00441-010-1090-5.
34. Strelau J, Sullivan A, Böttner M, Lingor P, Falkenstein E, Suter-Crazzolara C, et al. Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci. 2000;20:8597-8603.
35. Fuchs T, Trollor JN, Crawford J, Brown DA, Baune BT, Samaras K, et al. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline -the Sydney Memory and Aging Study. Aging Cell. 2013;12:882-889. doi: 10.1111/acel.12116.
36. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222. doi: 10.1056/NEJMoa022066.
37. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke. 2008;39:2712-2719. doi: 10.1161/STROKEAHA.107.513176.
38. Jiang J, Wen W, Brown DA, Crawford J, Thalamuthu A, Smith E, et al. The relationship of serum macrophage inhibitory cytokine-1 levels with gray matter volumes in community-dwelling older individuals. PLoS One. 2015;10:e0123399. doi: 10.1371/journal.pone.0123399.
39. Wallentin L, Zethelius B, Berglund L, Eggers KM, Lind L, Lindahl B, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One. 2013;8:e78797. doi: 10.1371/journal. pone.0078797.
40. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011;1385:8-17. doi: 10.1016/j.brainres.2011.02.045.
41. Ho JE, Larson MG, Ghorbani A, Cheng S, Vasan RS, Wang TJ, et al. Soluble ST2 predicts elevated SBP in the community. J Hypertens. 2013;31:1431-1436, discussion 1436. doi: 10.1097/HJH.0b013e3283611bdf.